Intestinal failure-associated metabolic bone diseases and response to teriparatide

Nutrition in Clinical Practice

Volumn 21, Issue 6, 2006, Pages 605-609

  Pazianas, Michael ^a   Compher, Charlene ^b,c   Schiavone Gatto, Phyllis ^c   Kinosian, Bruce P ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Penn Nursing ^*  (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCODONE; OXYCODONE; PARATHYROID HORMONE[1-34]; WARFARIN;

AGED; ARTICLE; BONE DENSITY; BONE MASS; BONE SCINTISCANNING; CASE REPORT; DISEASE ASSOCIATION; DRUG INTERMITTENT THERAPY; ENTEROPATHY; FEMALE; HOME CARE; HUMAN; KIDNEY DISEASE; METABOLIC BONE DISEASE; PARENTERAL NUTRITION; POSTMENOPAUSE; RADIATION EXPOSURE; SHORT BOWEL SYNDROME;

AGED; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; PARENTERAL NUTRITION, HOME; TERIPARATIDE;

EID: 33845242911     PISSN: 08845336     EISSN: None     Source Type: Journal    
DOI: 10.1177/0115426506021006605     Document Type: Article

References (17)

1. Haderslev K, Tjellesen L, Haderslev P, Staun M. Assessment of the longitudinal changes in bone mineral density in patients receiving home parenteral nutrition. JPEN J Parenter Enteral Nutr. 2004;28:289-294.
2. Cohen-Solal M, Baudoin F, Joly K, et al. Osteoporosis in patients on long-term home parenteral nutrition: a longitudinal study. J Bone Miner Res. 2003;18:1989-1998.
3. Pironi L, Labate AM, Pertkiewicz M, et al. Prevalence of bone disease in patients on home parenteral nutrition. Clin Nutr. 2002;21:289-296.
4. Verhage AH, Cheong WK, Allard JP, Jeejeebhoy KN. Increase in lumbar spine bone mineral content in patients on long-term parenteral nutrition without vitamin D supplementation. JPEN J Parenter Enteral Nutr. 1995;19:421-436.
5. de Vernejoul MC, Messing B, Modrowski D, Bielakoff J, Buisine A, Miravet L. Multifactorial low remodeling bone disease during cyclic total parenteral nutrition. J Clin Endocrinol Metab. 1985;60:109-113.
6. Pironi L, Tjellesen L, De Francisco A, et al. Bone mineral density in patients on home parenteral nutrition: a follow-up study. Clin Nutr. 2004;23:1288-1302.
7. National Osteoporosis Foundation. Osteoporosis: impact and overview. Available at: http://www.NationalOsteoporosisFoundation. org. Accessed September 15, 2005.
8. Iwamoto J, Takeda T, Sato Y. Effects of vitamin K2 on osteoporosis. Curr Pharm Des. 2004;10:2557-2576.
9. Miki T, Nakatsuka K, Naka H, et al. Effect and safety of intermittent weekly administration of human parathyroid hormone 1-34 in patients with primary osteoporosis evaluated by histomorphometry and microstructural analysis of iliac trabecular bone before and after 1 year of treatment. J Bone Miner Metab. 2004;22:569-576.
10. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434-1441.
11. El-Desouki M, Al-Jurayyan N. Bone mineral density and bone scintigraphy in children and adolescents with osteomalacia. Eur J Nucl Med. 1997;24:202-205.
12. Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R. Estimates of optimal vitamin D status. Osteoporos Int. 2005;16:713-716.
13. Shike M, Shils ME, Heller A, et al. Bone disease in prolonged parenteral nutrition: osteopenia without mineralization defect. Am J Clin Nutr. 1986;44:89-98.
14. Shike M, Sturtridge WD, Tam CS, et al. A possible role of vitamin D in the genesis of parenteral-nutrition-induced metabolic bone disease. Ann Intern Med. 1981;95:560-568.
15. Harrison JE, Jeejeebhoy KN, Track NS. The effect of total parenteral nutrition (TPN) on bone mass. In: Coburn JW, Klein GL, eds. Metabolic Bone Disease in Total Parenteral Nutrition. Baltimore, MD: Urban and Schwarzenberg; 1985:53.
16. Canada T. Aluminum exposure through parenteral nutrition formulations: mathematical versus clinical relevance. Am J Health Syst Pharm. 2005;62:315-318.
17. Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med. 2005;353:555-565.